The Lancet: Sinopharm vaccine is safe in boys 3-17 years old | generated a strong immune response

A recent study from the research journalLancet’s diseases threw it Sinopharm vaccine is safe and elicits a “strong immune response after two doses” in children aged 3 to 17 years.

Although its efficacy remains to be known, which will be evaluated in a phase III investigation, the journal’s specialists report that the so-called BBIBO-CorV is safe and well tolerated”, and that it “causes strong humoral responses (antibody generation) against infection with BBIBO-CorV.” SARS-CoV-2 after two doses”, based on stage I and II investigations in boys of that age group.

The trial carried out was a randomized, double-blind, and controlled trial. In both phases, we worked with healthy volunteers in the age groups 3–5 years, 6 and 12 years, and 13 and 17 years of age, who received different doses of immunization.

Regarding dosing, they were given 28 days apart. 445 children participated in the first stage, while 810 children were selected for the second stage.

Regarding safety, they noted that the most common adverse reaction was pain at the injection site, followed by fever, where “most severity was mild to moderate” and that it was “transient or resolved in a few days.”

Therefore, scientists at this point in the research concluded that the inactivated covid 19 BBIBP-CorV vaccine, known commercially as Sinopharm, was “safe and well-tolerated at all levels tested in participants aged 3 to 17 years.”

Furthermore, they added that adverse reactions mostly occurred after the first dose and showed a frequency similar to that seen in participants aged 18 to 59 years and in those aged 60 and over.

The researchers in this study expected that the third stage for this age group would be implemented in the United Arab Emiratess, where the vaccines will be administered 21 days apart to obtain additional data regarding safety, immunogenicity, and efficacy.